Loading…
Hosted by Unknown Host · 🇺🇸 US · EN · 23 episodes
Established thought leaders with verified media credentials.
The editorial team of The Lancet Infectious Diseases , in conversation with the journal’s authors, explores their latest research and its impact on people’s health, healthcare, and health policy. An audio companion to the journal, this podcast covers a broad range of topics, from mpox diagnostics in Africa, long COVID, adaptive trials in infectious diseases, tuberculosis drug development, and more.
Unknown Host hosts The Lancet Infectious Diseases in conversation with, a health show with 23 episodes published.
Fernando Tortosa and Ariel Izcovich discuss various aspects of hantavirus infections with a focus on the situation in Argentina, including transmission, epidemiology, clinical course, management, latest research developm
Dr Brecht Ingelbeen and Dr Daniel Valia join Senior Editor Phoebe Hall to discuss a new trial in the journal (the CABU-EICO trial) testing a co-created behavioural intervention bundle to improve antibiotic use, patient m
Sara Tartof and Matan Yechezkel discuss a new article in The Lancet Infectious Diseases about emerging doxycycline resistance against gonorrhoea and its wider implications for the implementation of doxycycline and the pr
Dr Jenny Clarke and Herve Semukunzi discuss a study they and colleagues recently published with us titled ‘Infection- and vaccine-induced mpox antibodies: validation of a combined mpox IgG ELISA during the clade 1b outbr
Dr Julia Moore Vogel and Dr Danilo Buonsenso discuss various aspects of long COVID including epidemiology, pathophysiology, underlying mechanisms, management, latest research developments, difficulties in conducting clin
Professors Steven Tong and Joshua Davis discuss all aspects of adaptive platform trials including advantages, disadvantages, differences from conventional trials, and tips for setting up and assessing them. They also hig
Professor Ana Odone, Dr Jesus Rodriguez-Manzano, and Dr Alex Howard discuss their new Series of papers on artificial intelligence and infectious diseases intended to support the infectious diseases community in understan
Drs Catherine Liu and Joshua Hill of the Fred Hutchinson Cancer Center discuss their new Series of papers on the prevention and management of infections in people who are immunocompromised, with a focus on prevention of
Lilian Tina Minja and Norbert Heinrich discuss the SUDUCO and DECODE trials in The Lancet Infectious Diseases on two new promising TB drugs, sutezolid and delpazolid, respectively. They also discuss the wider implication
Leonardo Basso and Juan Pablo Torres discuss their study in The Lancet Infectious Diseases on the effectiveness and impact of the first season of Chile's national immunisation programme with nirsevimab. They discuss the
Jan Felix Drexler and Fernando Bozza discuss their recent study published in the journal— “The spatio-temporal ecology of Oropouche virus: a laboratory-based modelling study across Latin America” and its wider implicatio
Prasad Kulkarni discusses a new Phase I trial in The Lancet Infectious Diseases on a dengue monoclonal antibody also known as VIS513 in healthy adults. In addition, he highlights the wider implications of this for dengue
Oriol Mitjà discusses a new trial in The Lancet Infectious Diseases on the use of oral linezolid compared with benzathine penicillin G for the treatment of early syphilis in adults. He also highlights what the trial mean
Sofia Viegas and Stefan Niemann discuss a new article in The Lancet Infectious Diseases about emerging bedaquiline resistance in Mozambique and its implications for drug resistant tuberculosis and the fight to end tuberc
Luciano Moreira and Henrik Salje discuss a new article in The Lancet Infectious Diseases describing the use of the Wolbachia bacteria to control the spread of mosquito-borne dengue and chikungunya in Rio de Janeiro, Braz
Richard Maude discusses a new article in The Lancet Infectious Diseases that assesses the efficacy of malaria chemoprophylaxis among forest goers in Cambodia. Read the full article: Antimalarial chemoprophylaxis for fore
Ben Cowling discusses a new article in The Lancet Infectious Diseases describing the protection that vaccines are providing against COVID-19 in Hong Kong. Read the full article: Vaccine effectiveness of one, two, and thr
Hugh Adler discusses a new article in The Lancet Infectious Diseases describing the management and the clinical features for seven patients with monkeypox hospitalised in the UK between 2018 and 2021. Read the full artic
Prof Beate Kampmann, Dr Karen Keddy, and Prof Peter Ghazal discuss a new cross-journal Series in The Lancet Infectious Diseases and EBioMedicine addressing the potential for and challenge of applying big data to childhoo
A new article highlights how changing immunity profiles motivate the need for better responses to outbreaks of polio in Africa. Read the full article: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
To pitch The Lancet Infectious Diseases in conversation with, visit https://lancetid.podbean.com for contact information, then craft a tight one-paragraph hook that ties your expertise to a gap in their recent health coverage.
The Lancet Infectious Diseases in conversation with is hosted by Unknown Host. The show is categorised under health (fitness) and has published 23 episodes.
The Lancet Infectious Diseases in conversation with has published 23 episodes.
The Lancet Infectious Diseases in conversation with regularly covers health, fitness, medicine. It sits in the health category, with a fitness focus.
The Lancet Infectious Diseases in conversation with is accessible for guests with genuine health expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
The Lancet Infectious Diseases in conversation with hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of The Lancet Infectious Diseases in conversation with average 23 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates The Lancet Infectious Diseases in conversation with's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 2 days ago.